FLDM stock opened at $3.71 on Friday. The firm has a market cap of $283.76 million, a price-to-earnings ratio of -4.76 and a beta of 1.14. The company has a quick ratio of 1.03, a current ratio of 1.45 and a debt-to-equity ratio of 0.68. Fluidigm has a 12-month low of $2.67 and a 12-month high of $7.51. The company’s fifty day simple moving average is $3.62 and its 200 day simple moving average is $4.14.
Fluidigm (NASDAQ:FLDM – Get Rating) last released its earnings results on Thursday, February 17th. The medical research company reported ($0.06) earnings per share (EPS) for the quarter. The firm had revenue of $38.27 million during the quarter. Fluidigm had a negative net margin of 45.36% and a negative return on equity of 40.15%.
Hedge funds have recently added to or reduced their stakes in the company. Macquarie Group Ltd. raised its holdings in shares of Fluidigm by 477.4% in the 3rd quarter. Macquarie Group Ltd. now owns 11,162 shares of the medical research company’s stock worth $74,000 after acquiring an additional 9,229 shares during the last quarter. Teacher Retirement System of Texas acquired a new stake in shares of Fluidigm in the 3rd quarter worth about $75,000. Metropolitan Life Insurance Co NY acquired a new stake in shares of Fluidigm in the 1st quarter worth about $151,000. Commonwealth Equity Services LLC acquired a new stake in shares of Fluidigm in the 4th quarter worth about $60,000. Finally, ProShare Advisors LLC acquired a new stake in shares of Fluidigm in the 4th quarter worth about $65,000. 76.59% of the stock is currently owned by institutional investors.
About Fluidigm (Get Rating)
Fluidigm Corporation creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology.
- Get a free copy of the StockNews.com research report on Fluidigm (FLDM)
- Institutions And Analysts Drive UnitedHealth Group Higher
- MarketBeat: Week in Review 4/11 – 4/15
- Three Beaten Down Mega Caps The Analysts Are Upgrading
- Top 3 Safe Stocks for Conservative Investors
- Array Technologies Stock Giving Another Ground Floor Entry
Receive News & Ratings for Fluidigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm and related companies with MarketBeat.com's FREE daily email newsletter.